Perseus Proteomics Inc
TSE:4882
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
300
837
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Perseus Proteomics Inc stock under the Base Case scenario is 760.55 JPY. Compared to the current market price of 642 JPY, Perseus Proteomics Inc is Undervalued by 16%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Perseus Proteomics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Perseus Proteomics Inc cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Perseus Proteomics Inc
Balance Sheet Decomposition
Perseus Proteomics Inc
Current Assets | 2.2B |
Cash & Short-Term Investments | 2.1B |
Receivables | 18m |
Other Current Assets | 20.4m |
Non-Current Assets | 42.9m |
Other Non-Current Assets | 42.9m |
Current Liabilities | 108.5m |
Accrued Liabilities | 45.8m |
Other Current Liabilities | 62.7m |
Non-Current Liabilities | 191.5m |
Other Non-Current Liabilities | 191.5m |
Earnings Waterfall
Perseus Proteomics Inc
Revenue
|
96.5m
JPY
|
Cost of Revenue
|
-11.8m
JPY
|
Gross Profit
|
84.6m
JPY
|
Operating Expenses
|
-966.6m
JPY
|
Operating Income
|
-882m
JPY
|
Other Expenses
|
-19.5m
JPY
|
Net Income
|
-901.5m
JPY
|
Free Cash Flow Analysis
Perseus Proteomics Inc
JPY | |
Free Cash Flow | JPY |
Profitability Score
Profitability Due Diligence
Perseus Proteomics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Perseus Proteomics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Perseus Proteomics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Perseus Proteomics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Perseus Proteomics Inc
According to Wall Street analysts, the average 1-year price target for Perseus Proteomics Inc is 816 JPY with a low forecast of 808 JPY and a high forecast of 840 JPY.
Dividends
Current shareholder yield for Perseus Proteomics Inc is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.
Contact
IPO
Employees
Officers
The intrinsic value of one Perseus Proteomics Inc stock under the Base Case scenario is 760.55 JPY.
Compared to the current market price of 642 JPY, Perseus Proteomics Inc is Undervalued by 16%.